-
Celgene CEO Weighs In On Receptos Deal And Its Timing
Wednesday, July 15, 2015 - 2:55pm | 336Read More...Celgene Corporation (NASDAQ: CELG) announced on Tuesday that it will be acquiring Receptos Inc (NASDAQ: RCPT) in a $7.3 billion deal. Robert Hugin, Celgene chairman and CEO, was on CNBC Wednesday to weigh in on the deal and its timing. Ozanimod: Key Driver "Exciting time for us and, I...
-
Celgene CEO: People And Embracing Change Are The Key To Our Success
Monday, February 2, 2015 - 8:49am | 316Read More...Robert Hugin, CEO and chairman of Celgene Corporation (NASDAQ: CELG), was recently on CNBC to talk about the company’s drug pipeline and Celgene’s success as a company. “You think about the change of the lives of the myeloma patient today from just 10-12 years ago, it was a...
-
Celgene CEO Explains The Reasons Behind Company's Ambitious Guidance
Tuesday, January 13, 2015 - 10:06am | 339Read More...Celgene Corporation (NASDAQ: CELG) witnessed a strong rally on Monday following the declaration of its preliminary 2014 results and the financial outlook for 2015 and beyond. The stock closed at $117, up more than $4. Robert Hugin, Celgene chairman and CEO, was on CNBC Monday to discuss...
